Precision Medicine in Oncology®

By individualizing risk of locoregional recurrence and radiosensitivity with molecular subtyping/genomic classifiers, it is hoped that use and/or extent of adjuvant radiation therapy could be tailored in early-stage breast cancer.

John L. Marshall, MD, discusses the push toward precision medicine in colorectal cancer.

The FDA has granted a priority review designation to pembrolizumab for the treatment of patients with unresectable or metastatic solid tumors with tissue tumor mutational burden-high status.

Gregory A. Otterson, MD, discusses when to start treatment with immunotherapy in patients with non–small cell lung cancer.

Benjamin P. Levy, MD, discusses emerging biomarkers and their respective therapies in lung cancer.

Circulating tumor DNA can be used as a predictive measure of response to neoadjuvant chemotherapy and inform overall prognosis in patients with early-stage breast cancer, providing information that can be used to tailor treatment.

Anis Hamid, MBBS, genitourinary oncology research fellow, Dana-Farber Cancer Institute, discusses the evolution of precision medicine in prostate cancer.

Serving as gatekeepers at the entry to the cell cycle, CDK4 and CDK6 make ideal therapeutic targets to block the unchecked proliferation that is a hallmark of cancer cells.

A Working Group of the European Society for Medical Oncology has determined that a decision tree on the sequential use of different tests in immunotherapy decision-making cannot be a general one for all cancers but should be designed on the basis of the specific tumor type.

Lynette M. Sholl, MD, discusses the evolving use of liquid and tissue biopsies for next-generation sequencing in the treatment paradigm for patients with lung cancer.